Inhibition of renal glucose reabsorption and reductions in plasma glucose levels achieved with SGLT2is occur independent of insulin levels or peripheral insulin resistance; thus, the risk of hypoglycemia is low with SGLT2i therapy [5,50]. The gene discussed is INS; the disease is Hypoglycemia.